22:18 , May 20, 2019 |  BioCentury  |  Product Development

Making Orphan drug prices work for society

The Orphan Drug Act worked too well. It didn’t just stimulate development of therapies for rare diseases, it reoriented huge swaths of the industry to the pursuit, all attracted by the high prices and product...
19:33 , May 17, 2019 |  BC Extra  |  Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
21:32 , May 13, 2019 |  BC Extra  |  Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
20:54 , May 8, 2019 |  BC Extra  |  Financial News

May 8 Financial Quick Takes: Trevi IPO, BMS, GeneQuantum

Trevi prices $55M IPO below range  Trevi Therapeutics Inc. (NASDAQ:TRVI) shares gained back some ground Wednesday -- adding $0.34 to $8.23 for the day -- after tumbling out of the gate on Tuesday, when it...
22:06 , May 7, 2019 |  BC Extra  |  Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU  The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
22:24 , May 6, 2019 |  BC Extra  |  Company News

Skyhawk signs neuro deal with Takeda as it prepares to expand its partnered indications

Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend...
21:16 , May 6, 2019 |  BC Extra  |  Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
23:29 , May 3, 2019 |  BioCentury  |  Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
22:52 , May 2, 2019 |  BC Extra  |  Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF  Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...